Asleh K, et al. - In a formal prospective-retrospective analysis of the phase III SBG0102 clinical trial randomizing metastatic breast cancer patients to gemcitabine-docetaxel or to single-agent docetaxel, significantly better overall survival was noted for patients with basal-like tumors by PAM50 gene expression in the gemcitabine arm. Researchers here evaluated the capacity of basal biomarkers nestin and inositol-polyphosphate-4-phosphate (INPP4B) to identify patients who may benefit from gemcitabine in the metastatic setting. They identified 239 cases as evaluable for this study, among these, 36 (15%) had been classified as basal-like by PAM50. Forty-one (17%) of the total cases had “Nestin+ or INPP4B−”, which was significantly associated with PAM50 basal-like subtype. In the metastatic setting, superior overall survival was noted for women with immunohistochemistry basal breast cancers defined as “nestin+ or INPP4B-” when these were randomized to gemcitabine-containing chemotherapy compared to docetaxel alone.